Smartkarma Daily Briefs

• Xuanzhu Biopharm, the biotech arm of HK-listed Sihuan Pharma, is seeking to raise at least USD 100m via a Hong Kong listing. The sole sponsor is CICC.
• In previous insight, we looked at the company’s core products and key products, including XBP-3571, XZP-3287, and XZP-3621, and its management team and investor backing.
• In this note, we look at the company’s PHIP updates.

• Newly Independent Company with Strong Market Positions: Solventum, a recent spin-off from 3M, is a global healthcare leader with established brands and significant market share in MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company is poised to benefit from increased focus and tailored capital allocation strategies.
• Financial Profile Presents Both Opportunities and Challenges: The company generates strong cash flow but is also saddled with a significant debt burden from the spin-off, making debt reduction a near-term priority. This could temper shareholder returns and strategic flexibility in the short term.
• Path to Value Creation Hinges on Execution: Solventum‘s success will depend on its ability to accelerate organic growth, expand margins, and innovate in its core markets. The recent divestiture of the Purification & Filtration business is a key step in streamlining the portfolio and focusing on higher-growth areas.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• LakeShore Biopharma received a non-binding privatization offer of $0.86/share from a consortium including its controlling shareholder.
• Crystal Peak Investments acquired a 51% stake at $0.71/share and seeks to buy remaining shares at $0.86/share.
• Oceanpine Capital, a consortium member, has historical ties to LSBCF, with its managing director previously serving as chairman.

• Summit Therapeutics is a clinical-stage biopharmaceutical company singularly focused on its lead asset, ivonescimab (SMT112), a novel, potentially first-in-class bispecific antibody targeting PD-1 and VEGF for the treatment of non-small cell lung cancer (NSCLC).
• The company’s strategy is heavily reliant on the success of its licensing partnership with Akeso Inc., which is responsible for the discovery and initial development of ivonescimab. Summit holds the rights for development and commercialization in the US, Canada, Europe, and Japan.
• Financially, Summit is a pre-revenue entity with significant net losses driven by substantial R&D and clinical trial expenses. Its future is contingent on positive readouts from pivotal Phase III trials (HARMONi, HARMONi-3) and subsequent regulatory approvals, which face a highly competitive oncology market.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Three Core Products need to face fierce competition, and there’re other similar products being included in NRDL reimbursement or VBP. So, we’re not optimistic about the commercialization performance of Xuanzhu.
• The A-share listing committee had doubts about Xuanzhu’s pipeline strength and future commercialization outlook. So, Xuanzhu’s A-share IPO failed. The peak sales of three core products could be just RMB800mn-1bn. 
• Considering Xuanzhu’s unsatisfactory growth outlook, market value is just RMB2.4-3 billion. This means that Xuanzhu is overvalued, and reasonable valuation could be even lower than that after Series B Financing.

• Strong Brand Equity and Market Leadership: Yunnan Baiyao is a household name in China with a dominant position in the Traditional Chinese Medicine (TCM) sector, particularly with its core Yunnan Baiyao product line. The company has successfully leveraged its brand to diversify into high-growth consumer health products, such as toothpaste, where it holds a leading market share.
• Diversified Business Model with Growth Potential: The company operates a vertically integrated model and has expanded from its core pharmaceutical business into health products, personal care, and TCM resources. This diversification provides multiple revenue streams and opportunities for future growth, with a strategic focus on innovation and expansion into new areas like medical aesthetics.
• Solid Financial Performance and Shareholder Returns: Yunnan Baiyao has demonstrated consistent revenue growth and strong profitability. The company maintains a healthy financial position and has a track record of returning value to shareholders through dividends.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Regeneron’s growth is propelled by the strong performance of its blockbuster drugs, Eylea and Dupixent, alongside a promising and extensive late-stage pipeline, particularly in oncology and immunology.
• The company’s proprietary VelociSuite® technology platform serves as a significant competitive advantage, enabling the rapid and efficient discovery and development of novel, fully human antibody-based therapies.
• Key challenges include heavy revenue concentration on Eylea and Dupixent, and the looming threat of biosimilar competition for Eylea, which could impact future revenue streams despite recent legal victories delaying entry.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Medtronic stands as a global leader in medical technology, with a highly diversified portfolio across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes segments, which provides resilience and broad market reach.
• The company is focused on driving growth through innovation in high-margin areas, including cardiac ablation, structural heart, surgical robotics (Hugo™ RAS system), and diabetes care (MiniMed™ 780G system), supported by a robust R&D pipeline.
• While facing challenges such as intense competition, stringent regulatory hurdles, and supply chain complexities, Medtronic’s strong financial health, consistent dividend growth, and strategic focus on emerging markets position it for long-term value creation.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Bristol-Myers Squibb is a global biopharmaceutical company facing a significant patent cliff for key revenue drivers like Eliquis and Opdivo, creating near-term revenue headwinds.
• The company’s strategy to mitigate these losses centers on its growing portfolio of new products, a robust R&D pipeline focused on oncology, immunology, and cardiovascular diseases, and strategic acquisitions to replenish its drug pipeline.
• While navigating a challenging period of patent expirations and increasing competition, the company’s strong cash flow, commitment to its dividend, and investments in innovative platforms like cell therapy and radiopharmaceuticals present a long-term growth thesis.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Biogen is in a pivotal transition phase, shifting from its declining, legacy multiple sclerosis (MS) franchise to a new portfolio focused on high-unmet-need neurological and rare diseases.
• Future growth hinges on the successful commercialization of its new products, primarily Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s ataxia, and Zurzuvae for postpartum depression. The uptake of these drugs has been gradual but is accelerating.
• Under the leadership of CEO Christopher Viehbacher, the company is executing a significant cost-saving program, “Fit for Growth,”to improve profitability and fund strategic initiatives, including external collaborations and potential acquisitions to bolster its pipeline.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.
• In this insight, we take a look at the potential ADDs and DELs leading the race for the semiannual index rebal event in December 2025.
• We expect up to six ADDs and six DELs for the CSI Medical Service index during this index review event based on the latest available data.

• The data in this insight is collated from the “shareholding disclosure” link on the HKEx website.
• Often there is a corresponding HKEx announcement on the increase – or decrease – in the shareholding by directors. However, such disclosures are by no means an absolute.
• These insights also flag those companies where shares have been pledged, both recently and ongoing.

• Butong Group (BUTONG HK) raised around US$100m in its Hong Kong IPO.
• Butong focuses on the mid to high-end segment of China’s nursery product market.
• We have looked at the company’s background and pricing in our earlier note, in this note we talk about the trading dynamics.

• FDA has cleared Merck’s Keytruda subcutaneous injection, which has been developed using Alteogen Inc (196170 KS)’s human hyaluronidase ALT-B4. EMA’s CHMP also recommended approval of subcutaneous Keytruda.
• Merck expects 30–40% of Keytruda IV sales to be converted to SC by 2028. Accordingly, Alteogen is expected to secure over KRW1T in annual royalties in the long term.
• Keytruda SC launch in the U.S. and EU, additional deals for ALT-B4, and Enhertu SC Phase 1 trial update are the key upcoming catalysts for Alteogen.

• News agency Kyodo News notes that “a rising number of wealthy Chinese tourists visit Japan primarily for medical services,” and the company’s CEO notes that “the Japanese medical sector has two viable paths for growth: we must either attract more international patients or bring Japanese medical expertise abroad,” & SBC is pursuing both strategies, using a disciplined financial approach.
• SBC recently appointed Dr. Ewen Chee, founder of AHH, President of AHH and Lead Doctor for Asia Strategy to support its global strategy.

• Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world.
• Pivotal studies have been completed with safety & efficacy results exceeding expectations.
• Achieve is now awaiting its target action date of June 20th 2026 and preparing for commercialization.

• On August 15, 2025, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the U.S. Food and Drug Administration (FDA) approved Tonmya (cyclobenzaprine HCl sublingual tablet) for the treatment of fibromyalgia.
• Tonmya is the first FDA approved therapy for fibromyalgia in over 15 years.
• The approval was based in part on data from two double blind, placebo controlled Phase 3 trials of nearly 1,000 patients in total that showed Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint.